Award
National Cancer Institute 5R44CA290913-03
Development of small molecule therapeutics targeting AR-V7 for prostate cancer
Recipient
Not specified
Award Amount
$888,779.00
Ceiling
$888,779.00
Awarded
May 02, 2024
Identifier
5R44CA290913-03
NIH awarded a grant for developing small molecule therapeutics targeting AR-V7 for prostate cancer, including medicinal chemistry and efficacy studies.
Description
This is a NIH grant project for developing dual inhibitors of androgen receptor variants for prostate cancer treatment, with a focus on AR-V7. The project includes medicinal chemistry, toxicity studies, efficacy evaluation, and manufacturing.